QuidelOrtho Corporation Common Stock (QDEL)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and need little debt. QuidelOrtho is a diagnostics company with 6,500 employees, operating in labs, transfusion medicine, point of care, and molecular diagnostics. The filed record shows trouble. In fiscal 2023, the year ended 2023-12-31, revenue was $3.0B and net loss was only $10.1M. By fiscal 2024, ended 2024-12-29, revenue was $2.8B and net loss was $2.1B; in fiscal 2025, ended 2025-12-28, revenue was $2.7B and net loss was $1.1B. Recent quarters: in fiscal Q2 2026, ended 2026-06-28, revenue was $630.9M with a $92.9M net loss and diluted EPS of -$1.36; in fiscal Q1 2026, ended 2026-03-29, the net loss was $91.8M. Losses are smaller than the severe fiscal Q3 2025 loss of $733.0M, in the quarter ended 2025-09-28, but they are still losses. At the 2026-10-13 close of $14.10, FairStock calculations show a negative P/E, price/book of 0.54, ROE of -45.91%, ROCE of 0.38%, debt/equity of 1.73, trailing free cash flow of -$211.2M, FCF yield of -21.8%, Piotroski F-score of 3/9, and Altman Z-score of 0.04. That Altman figure points to serious financial distress. The P/B is superficially cheap, but book value matters only if the business can stop burning cash. A durable moat would show stable pricing and margins; here revenue has declined and cash flow is negative. The Lynch category is TURNAROUND—loss in the latest year after earlier profits. Turnarounds can work, but Graham would demand a balance sheet that can survive the wait. I would want evidence of positive free cash flow, debt reduction, and consistent net income before calling this a sound value situation.

In plain English: QuidelOrtho makes medical diagnostic tests and laboratory equipment. The business looks weak right now: it has lost money in recent years and is using more cash than it brings in, though the losses in the first half of fiscal 2026 were smaller than the worst losses of 2025. At $14.10 on 2026-10-13, the shares look cheap compared with the company's recorded net assets, but the money-losing operations make that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-28) · fiscal Q1 2026 10-Q (period ended 2026-03-29) · fiscal Q3 2025 10-Q (period ended 2025-09-28) · fiscal Q2 2025 10-Q (period ended 2025-06-29) · FY2025 10-K (period ended 2025-12-28) · FY2024 10-K (period ended 2024-12-29) · FY2023 10-K/A (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer